Protagonist Therapeutics (PTGX)
(Real Time Quote from BATS)
$61.01 USD
+2.42 (4.13%)
Updated Sep 17, 2025 11:10 AM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTGX 61.01 +2.42(4.13%)
Will PTGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Other News for PTGX
Protagonist Therapeutics (PTGX) Unveils Promising Phase 3 Trial Data for Psoriasis Treatment
Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM
Protagonist Therapeutics announces presentations of icotrokinra data
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
H.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)